ArticleWorld journal of surgical oncology2026
miR-19a-3p accelerates the development of melanoma and reduces the prognosis of patients.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPrevious studies have shown that miR-19a-3p is expressed at higher levels in melanoma tissues, suggesting that it may be involved in the progression of melanoma. This study sought to elucidate the biological function of miR-19a-3p in melanoma.
methodsIn this study, RT-qPCR was performed to measure the expression level of miR-19a-3p in melanoma tissues and cell lines. The relationship between miR-19a-3p and the prognosis of melanoma patients was assessed by Kaplan-Meier analysis and the Cox regression model. The effects of miR-19a-3p on cell proliferation, migration, and invasion were analyzed by Cell Counting Kit-8 (CCK-8) and Transwell assays. The targeting relationship between miR-19a-3p and adrenergic receptor β1 (ADRB1) was verified by Dual-luciferase reporter assay.
resultsmiR-19a-3p was significantly overexpressed in melanoma tissues and cell lines. The high expression of miR-19a-3p was significantly associated with a higher TNM stage, lymph node metastasis, and decreased survival rate. Inhibition of miR-19a-3p could significantly weaken the proliferation, migration, and invasion abilities of melanoma cells. ADRB1 was a direct target of miR-19a-3p, and their expressions were negatively correlated. Knockdown of ADRB1 reversed the anti-tumor effect of miR-19a-3p inhibitor.
conclusionmiR-19a-3p promoted the malignant progression of melanoma by targeting and inhibiting ADRB1. Its expression level can serve as an independent biomarker for evaluating the prognosis of melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.